Emerging antidyslipidemic drugs

Expert Opinion on Emerging Drugs

Volumn 13, Issue 2, 2008, Pages 363-381

  Pollex, Rebecca L ^a   Joy, Tisha R ^a   Hegele, Robert A ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Biotherapeutics; Cholesterol; Combination therapy; Coronary heart disease; Dyslipidemia; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Statins; Triglyceride

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; AEGR 733; ALN PCS01; ANABOLIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; AVE 5530; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; BMS 201038; COLESTILAN; CORTICOSTEROID; CRD 5; DIGOXIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FM VP4; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISIS 301012; LAPAQUISTAT; LEVOTHYROXINE; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MD 0727; MERCK 0524A; MOPERONE; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PITAVASTATIN; ROSUVASTATIN; RVX 208; SIMCOR; TAK 475; THIAZIDE DIURETIC AGENT; TREDAPTIVE; TRIACYLGLYCEROL; UNINDEXED DRUG; WARFARIN;

ABDOMINAL DISTENSION; AMINOTRANSFERASE BLOOD LEVEL; BLOATING; CHOLELITHIASIS; CLINICAL TRIAL; CONSTIPATION; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESEARCH; DYSLIPIDEMIA; FATTY LIVER; FLUSHING; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; INSULIN SENSITIVITY; MYALGIA; MYOSITIS; NONHUMAN; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STEATORRHEA; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CORONARY DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 46849105477     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.2.363     Document Type: Review

References (136)

1. Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006;113:647-56
2. Johansen H, Nair C. The changing face of heart disease and stroke in Canada 2000. In: Wielgosz A, Arango M, Carew M, Ferguson M, Johansen H, Nair C, et al., editors. Health Outcomes. Ottawa, Canada: Heart and Stroke Foundation of Canada; 1999. p. 65-85
3. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
5. Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-8
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
7. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116:3090-100
8. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8
9. Abbott RD, Wilson PW, Kannel WB, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 1988;8:207-11
10. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41
11. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008;7:143-55
12. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005;36:232-40
13. Hussain MM, Fatma S, Pan X, et al. Intestinal lipoprotein assembly. Curr Opin Lipidol 2005;16:281-5
14. Shelness GS, Sellers JA. Very-low-density lipoprotein assembly and secretion. Curr Opin Lipidol 2001;12:151-7
15. Vance DE, Vance JE. Biochemistry of lipids, lipoproteins and membranes. 4th edition. Amsterdam: Elsevier Science; 2002
16. Karpe F, Steiner G, Uffelman K, et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97
17. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16
18. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
19. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007;26:38-48
20. Pipeline insight: Antidyslipidemics - The power of two. Market Research.com, 2005. Available from: http://www.marketresearch. com/search/results.asp?sid=97553088-4058l4861-501265549&query= antidyslipidemic&vendorid= 72&publisher=Datamonitor [Last accessed 26 February 2008]
21. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86
22. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
23. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
24. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
25. Superko HR, King S 3rd. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008; 117:560-8; discussion 68
26. Mays ME, Dujovne CA. Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia? Curr Atheroscler Rep 2008;10:45-52
27. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003;139:670-82
28. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
29. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
30. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
31. Ahn SC. Neuromuscular complications of statins. Phys Med Rehabil Clin North Am 2008;19:47-59
32. Sueta CA, Massing MW, Chowdhury M, et al. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J Card Fail 2003;9:36-41
33. Hoeg JM. Pharmacologic and surgical treatment of dyslipidemic children and adolescents. Ann NY Acad Sci 1991;623:275-84
34. Melian EB, Plosker GL. Colesevelam. Am J Cardiovasc Drugs 2001;1:141-6; discussion 47-8
35. Leren TP, Hjermann I, Berg K, et al. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988;73:135-41
36. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA 1987;257:33-8
37. Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(Suppl l):S53-8
38. Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-205
39. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13
40. Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPAR-alpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 2007;48:2725-35
41. Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C-18C
42. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97:27C-31C
43. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
44. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8
45. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
46. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
47. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154:943-53
48. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007;14:99-108
49. Knopp RH, Gittet H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
50. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7
51. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15
52. McKenneyJM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-7
53. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008;62:88-96
54. Malik S, Kashyap ML. Niacin, lipids, and heart disease. Curr Cardiol Rep 2003;5:470-6
55. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5
56. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003;278:9869-74
57. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003;303:364-9
58. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
59. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7
60. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81
61. Charlton-Menys V, Durrington PN. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential. Drugs 2007;67:11-6
62. Burnett JR, Huff Ml Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin Investig Drugs 2006;15:1337-51
63. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of the acyl coenzyme Axholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004;110:3372-7
64. Rudel LL, Lee RG, Cockman TL. Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol 2001;12:121-7
65. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997;1345:136-50
66. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258:999-1001
67. Liao W, Hui TY, Young SG, et al. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res 2003;44:978-85
68. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998;282:751-4
69. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74
70. Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985;58:175-86
71. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8
72. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007;48:1263-72
73. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
74. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
75. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
76. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
77. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
78. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257-60
79. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
80. Segrest JP, Li L, Anantharamaiah GM, et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000;11:105-15
81. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000;41:1481-94
82. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Nad Acad Sci USA 1994;91:9607-11
83. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001;42:545-52
84. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an ApoA-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002;105:290-2
85. Ou J, Wang J, Xu H, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 2005;97:1190-7
86. Ou J,Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003;107:2337-41
87. Li X, Chyu KY, Faria Neto JR, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004;110:1701-5
88. Franceschini G, Sirtori CR, Capurso A 2nd, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892-900
89. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
90. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
91. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
92. Goff DC Jr, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:4i-20i
93. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-55
94. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371-8
95. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007;18:304-9
96. Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008
97. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6
98. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72
99. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-4
100. Akdim F, Harchaoui KE, Stroes ES, et al. Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012. Future Lipidol 2007;2:387-93
101. Kramer W, Corsiero D, Girbig F, et al. Rabbit small intestine does not contain an annexin II/caveolin 1 complex as a target for 2-azetidinone cholesterol absorption inhibitors. Biochim Biophys Acta 2006;1758:45-54
102. A study evaluating the safety and efficacy of AVE5530 (4 weeks) in patients with mild to moderate hypercholesterolemia, NCT00440154, 2008. Available from: http://www.clinicaltrials.gov [Last accessed 16 March 2008]
103. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-56
104. Aggarwal D, West KL, Zern TL, et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005;5:30
105. Homma Y, Kobayashi T, Yamaguchi H, et al. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Atherosclerosis 1997;129:241-8
106. Asami T, Uchiyama M. Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin. Atherosclerosis 2002;164:381-2
107. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53-8
108. Shneider BL. Intestinal bile acid transport: biology, physiology, and pathophysiology. J Pediatr Gastroenterol Nutr 2001;32:407-17
109. Zhang EY, Phelps MA, Cheng C, et al. Modeling of active transport systems. Adv Drug Deliv Rev 2002;54:329-54
110. Kitayama K, Nakai D, Kono K, et al. Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur J Pharmacol 2006;539:89-98
111. Wasan KM, Najafi S, Wong J, et al. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water-soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharm Sci 2001;4:228-34
112. Looije NA, Risovic V, Stewart DJ, et al. Disodium ascorbyl phytostanyl phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model. J Pharm Pharm Sci 2005;8:400-8
113. Lukic T, Wasan KM, Zamfir D, et al. Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Metabolism 2003;52:425-31
114. Ramaswamy M, Yau E, Wasan KM, et al. Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. J Pharm Pharm Sci 2002;5:29-38
115. Wasan KM, Yau E, Boulanger KD, et al. Effects of disodium ascorbyl phytostanol phosphates (FM-VP4) on cholesterol accumulation within rat intestinal cells. AAPS PharmSci 2003;5:E6
116. Forbes Medi-Tech, Inc., FM-VP4: a new class of cholesterol lowering drugs, 2008. Available from: http://www. forbesmedi.com/s/FM-VP4.asp [Last accessed 6 February 2008]
117. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54
118. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
119. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14
120. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
121. Lai E, De Lepeleire I, CrumleyTM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:849-57
122. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. ClinicalTrials.gov, 2007. Available from: http://www.clinicaltrials.gov/ct/show/ NCT00461630?order=6 [Last accessed 15 February 2008]
123. Stamler CJ, Breznan D, Neville TA, et al. Phosphatidylinositol promotes cholesterol transport in vivo. J Lipid Res 2000;41:1214-21
124. Burgess JW, Boucher J, Neville TA, et al. Phosphatidylinositol promotes cholesterol transport and excretion. J Lipid Res 2003;44:1355-63
125. Burgess JW, Neville TA, Rouillard P, et al. Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res 2005;46:350-5
126. Pandey NR, Renwick J, Misquith A, et al. Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion. Biochemistry 2008;47:1579-87
127. Liponex, Inc. CRD5 Science. Available from: http://www.liponex.ca/ science/crd5.html [Last accessed 6 February 2008]
128. Liponex updates CRD5 status and corporate strategy (News: December 13, 2007). Available from: http://www.liponex.ca/ut/ pdf/12.13.07%20Liponex%20 Updates%20CRD5%20Status.pdf [Last accessed 6 February 2008]
129. Gillard BK, Courtney HS, MasseyJB, et al. Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption. Biochemistry 2007;46:12968-78
130. Alnylam presents first ever non-human primate data with an RNAi therapeutic targeting PCSK9 showing significant and durable reductions in LDL cholesterol levels, 2007. Available from: http://phx.corporate-ir.net/phoenix. zhtml?c=148005&p=irol-newsArticle2&I D=1059699&highlight= [Last accessed 26 February 2008]
131. Bristol-Myers Squibb enters cardiovascular disease collaboration with Isis Pharmaceuticals, 2007. Available from: http://ir.isispharm.com/ releasedetail. cfm?ReleaseID=241674 [Last accessed 28 February 2008]
132. Akdim F, Stroes ES, Kastelein JJ. Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 2007;18:397-400
133. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-35
134. Isis reports positive results of phase 2 study of ISIS 301012 in heterozygous FH patients, 2007. Available from: http://ir.isispharm.com/ releasedetail. cfm?ReleaseID=267339 [Last accessed 3 March 2008]
135. Isis Pharmaceuticals updates its positive phase 2 data for ISIS 301012 in familial hypercholesterolemia patients, 2007. Available from: http://ir.isispharm.com/ releasedetail.cfm?ReleaseID=244309 [Last accessed 28 February 2008]
136. Isis reports new data for mipomersen in routine high cholesterol patients and provides cumulative safety summary, 2007. Available from: http://ir.isispharm.com/ releasedetail.cfm?ReleaseID=275455 [Last accessed 28 February 2008]